Background: Meta-analysis was used to compare the difference between 3D reconstruction technology and 2D computed tomography (CT) before surgery for primary hepatic carcinoma (PHC) and to systematically evaluate the application value of 3D vascular reconstruction and 3D navigation technology in guiding precise liver resection for PHC. However, there are still many controversies in this aspect, and there are no clear conclusions on the effectiveness and safety of three-dimensional vascular reconstruction combined with three-dimensional navigation in laparoscopic hepatectomy. Therefore, it is necessary to systematically review the results of previous studies with meta method in this study to determine their clinical efficacy and complications and guide clinical treatment.Methods: We used the Cochrane Library, PubMed, Embase, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodicals Full-Text Database (VIP), and Wanfang database to conduct an online search for data from randomized controlled trials of preoperative 3D reconstruction versus conventional CT in hepatectomy published up to October 2021. Relevant literature was selected based on the inclusion criteria, data was extracted, and quality evaluation of the included literature was carried out. I 2 test was used to evaluate heterogeneity among the studies, and Cochrane risk of bias 2.0 was used to evaluate the studies.Results: A total of 16 studies were included in this study. Meta-analysis showed that there were statistically significant differences between the 3D vascular reconstruction group and conventional surgery group in operation time [mean differences (MD)

No abstract

Background: Gallbladder cancer (GBC) is a common biliary tract malignancy worldwide, with no definite molecular-targeted treatment. Previous studies have shown that miR-539-5p was observed to be aberrantly expressed in multiple tumors and was associated with the occurrence and progression of human cancers. However, the functional role and exact mechanism of miR-539-5p in GBC progression remain barely known.Methods: The expression of miR-539-5p and BACH1 in GBC tissues and cell lines was detected by qRT-PCR. Western blotting was utilized to detect the protein level of BACH1. CCK-8 assay, colony formation assay, and Transwell assay was employed to evaluate GBC cell proliferation and invasion. Dual-luciferase reporter gene assay was utilized to verify the target relationship between miR-539-5p and BTB domain and CNC homolog 1 (BACH1). Xenograft tumor experiments were conducted on nude mice to confirm antitumor effect of miR-539-5p on GBC in vivo.Results: Our results showed that miR-539-5p was downregulated in GBC tissues and cell lines. Overexpression of miR-539-5p significantly suppressed the proliferation and invasion abilities of GBC cells. Dual-luciferase reporter gene assay confirmed that BACH1 was a target gene of miR-539-5p. Moreover, knockdown of BACH1 exhibited anti-proliferation and anti-invasion effects on GBC cells. Mechanistically, miR-539-5p suppressed the malignant behaviors of GBC cells, which were largely counteracted by the overexpression of BACH1. In vivo experiments, miR-539-5p overexpression tremendously repressed GBC tumor growth.Conclusion: miR-539-5p inhibited GBC progression via directly targeting BACH1, which can be served as potential treatment targets against the progression of GBC.